Treatment Regret in Prostate Cancer Patients Associated with Cardiovascular Co-morbidity

Share this content:

(ChemotherapyAdvisor) – Cardiovascular co-morbidity is associated with increased treatment regret among men with recurrent prostate cancer, according to a team of US-based researchers. The conclusion is based on a study of the same name, which was published in the July issue of the British Journal of Urology International.

In this study, the investigators aimed to determine whether cardiovascular co-morbidity is associated with increased treatment regret among men with recurrent prostate cancer. To make this determination, the investigators analyzed a study cohort of 795 men in the Comprehensive, Observational, Multi-center, Prostate Adenocarcinoma (COMPARE) registry who had experienced biochemical recurrence at a median of 5.5 years after prostatectomy, external beam radiation therapy, brachytherapy, or primary androgen deprivation therapy.

“Cardiovascular co-morbidity, which included myocardial infarction, congestive heart failure, angina, diabetes, stroke or circulation problems, was defined using a validated two-question screening process after adjusting for sociodemographic and treatment factors and post-treatment bladder and bowel toxicity,” the investigators wrote.

It was reported that 14.8% of the 795 evaluable men reported regret. Factors associated with increased treatment regret included cardiovascular co-morbidity (adjusted odds ratio [AOR]= 1.52 [95% CI:1.00–2.31], P=0.048); younger age (AOR: 0.97 [95% CI 0.94–0.99] per year increase in age, P=0.019); and bowel toxicity after treatment (AOR 1.58 [95% CI 1.03–2.43], P=0.038).

Based on the results of this study, the investigators concluded: “Among men with recurrent prostate cancer, those with cardiovascular co-morbidity were >50% more likely to experience treatment regret than men without cardiovascular co-morbidity. These data provide a rationale for men with cardiovascular co-morbidity to give additional consideration to active surveillance for their newly diagnosed prostate cancer.”



Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs